World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
33930
World Ranking
10059
National Ranking
5178

Oliver W. Press publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Oliver W. Press sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 504 publications — 59th percentile

59% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Oliver W. Press D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Oliver W. Press sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Oliver W. Press was affiliated with the University of Washington in the United States. Their research primarily focused on Medicine, with notable contributions in Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging, Oncology, Immunology, and Hematology.

The scientist's work encompassed several key topics, including:

  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Monoclonal and Polyclonal Antibodies Research
  • Radiopharmaceutical Chemistry and Applications
  • Immunotherapy and Immune Responses
  • Multiple Myeloma Research and Treatments
  • Hematopoietic Stem Cell Transplantation

Among their recent papers were:

  • 90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma (2020), published in Bone Marrow Transplantation
  • Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma (2020), published in Transplantation and Cellular Therapy
  • Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA (2020), published in Molecular Cancer Therapeutics
  • A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma (2020), published in American Journal of Hematology
  • Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma (2021), published in Blood Advances

Frequent publication venues for Oliver W. Press included:

  • Transplantation and Cellular Therapy
  • Bone Marrow Transplantation
  • Molecular Cancer Therapeutics
  • Journal of Nuclear Medicine
  • American Journal of Hematology

Collaborations were an important aspect of their research career. Frequent co-authors included:

  • Damian J. Green
  • Ajay K. Gopal
  • Brenda M. Sandmaier
  • Darrell R. Fisher
  • John M. Pagel

Oliver W. Press was recognized as a Member of the Association of American Physicians. The scientist's work contributed to a range of studies within hematology, oncology, and immunotherapy fields before their passing.

Best Publications

  • Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

    Brian G. Till;Brian G. Till;Michael C. Jensen;Jinjuan Wang;Eric Y. Chen

  • Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies

    Daming Shan;Jeffrey A. Ledbetter;Oliver W. Press

  • Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

    Oliver W. Press;Janet F. Eary;Frederick R. Appelbaum;Paul J. Martin

  • CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

    Brian G. Till;Brian G. Till;Michael C. Jensen;Michael C. Jensen;Jinjuan Wang;Xiaojun Qian

  • Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas

    M. S. Kaminski;A. D. Zelenetz;O. W. Press;M. Saleh

  • Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas

    OW Press;F Appelbaum;JA Ledbetter;PJ Martin

  • Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.

    Daming Shan;Jeffrey A. Ledbetter;Oliver W. Press

  • Hickman Catheter Infections in Patients With Malignancies

    Oliver W. Press;Paul G. Ramsey;Eric B. Larson;Alexander Fefer

  • Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas

    O.W Press;O.W Press;F Appelbaum;F Appelbaum;P.J Martin;P.J Martin;D.C Matthews;D.C Matthews

  • Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

    Adam M Petrich;Mitul Gandhi;Borko Jovanovic;Jorge J Castillo

  • Radioimmunotherapy of human tumours

    Steven M. Larson;Jorge A. Carrasquillo;Nai Kong V Cheung;Oliver W. Press

  • New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma

    Richard I. Fisher;Michael LeBlanc;Oliver W. Press;David G. Maloney

  • Non-Hodgkin's Lymphomas

    Andrew D. Zelenetz;Ranjana H. Advani;John C. Byrd;Myron S. Czuczman

  • NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

    Zelenetz Ad;Abramson Js;Advani Rh;Andreadis Cb

  • Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.

    O W Press;J F Eary;C C Badger;P J Martin

  • Evaluation and Management of Chylous Ascites

    Oliver W. Press;Nancy Ottman Press;Sheldon D. Kaufman

  • Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.

    Steven Y. Liu;Janet F. Eary;Stephen H. Petersdorf;Paul J. Martin

  • Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome

    Dana C. Matthews;Dana C. Matthews;Frederick R. Appelbaum;Frederick R. Appelbaum;Janet F. Eary;Janet F. Eary;Darrell R. Fisher;Darrell R. Fisher

  • Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911

    Oliver W. Press;Joseph M. Unger;Rita M. Braziel;David G. Maloney

  • A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.

    Oliver W. Press;Janet F. Eary;Ted Gooley;Ajay K. Gopal

Frequent Co-Authors

David G. Maloney
David G. Maloney Fred Hutchinson Cancer Research Center
Ted Gooley
Ted Gooley Fred Hutchinson Cancer Research Center
William I. Bensinger
William I. Bensinger Fred Hutchinson Cancer Research Center
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center
Brenda M. Sandmaier
Brenda M. Sandmaier Fred Hutchinson Cancer Research Center
Rainer Storb
Rainer Storb Fred Hutchinson Cancer Research Center
Irwin D. Bernstein
Irwin D. Bernstein Fred Hutchinson Cancer Research Center
Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
Julie M. Vose
Julie M. Vose University of Nebraska Medical Center
Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond traditional medical school, a variety of related online degrees offer new routes and faster advancement. Many licensed nurses, for example, are looking to complete their Bachelor of Science in Nursing. rn to bsn programs no clinicals are increasingly popular for their flexibility, as they allow working RNs to earn their degree online without additional in-person clinical demands.

If you're aiming for the highest levels of nursing practice, consider advanced pathways such as dnp programs online. These Doctorate of Nursing Practice degrees are designed for quick completion and flexibility. There are also specialized options for those who value efficiency, including dnp programs online that focus on ease of completion for working professionals.

For those just starting out, accelerated programs like 9 month lpn program pathways provide entry into nursing in less than a year. These programs are ideal for individuals eager to join the healthcare workforce quickly, and can later be a stepping stone to advanced degrees.

Best Scientists Citing Oliver W. Press

Recently Published Articles